Drugs / AB-205
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03925935 | May 2019 → Nov 2020 | Hodgkins lymphoma, non-Hodgkin lymphoma | Angiocrine Bioscience | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05181540 | Feb 2022 → Dec 2023 | Hodgkins lymphoma, non-Hodgkin lymphoma | Angiocrine Bioscience | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-02-08 | Angiocrine Bioscience | Results Results of an Open Label Dose Escalation Trial of AB-205 (E-CEL® cells) in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) angiocrinebioscience.com ↗
AB-205 is an experimental engineered-cell therapy designed to accelerate regeneration of organs and eliminate or reduce SRRT. |
| 2020-12-05 | Angiocrine Bioscience | Results Results of a Phase 1 Open Label Dose Escalation Trial of AB-205 (Allogeneic Engineered Endothelial Cell Therapy) in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) angiocrinebioscience.com ↗
Here we report results of a Phase I study of AB-205 in adults with lymphoma undergoing HDT-AHCT. |
All press releases naming this drug 5 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AB-205 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03925935 ↗ |
| Modality | Cell therapy | “Engineered human umbilical vein endothelial cells” NCT03925935 ↗ |